Spectrum Pharmaceuticals Announces Promotion Of Joseph Turgeon To Senior Vice President And Chief Commercial Officer As Company Builds On Recent Commercial Reorganization To Advance Growth And Market Penetration Over The Next Five Years

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer (CCO). Mr. Turgeon joined Spectrum in October 2012 as Senior Vice President Sales & Commercial Operations, bringing over 25 years of pharma sales experience, including various executive leadership roles at Amgen. In his new capacity as CCO, Mr. Turgeon will be responsible for global commercial and sales activities, reporting to Spectrum Pharmaceuticals’ Executive Vice President, Chief Operating Officer, Ken Keller. Currently, Spectrum markets three oncology products in the U.S. – FUSILEV® (levoleucovorin) for Injection; FOLOTYN® (pralatrexate injection); and ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use – with ex-U.S. rights for ZEVALIN as well.

"As we reported in our presentation earlier this week at the Annual J.P. Morgan Healthcare Conference, Spectrum is committed to continued strong growth over the next five years, with three anticancer drugs on the market and nearly ten drugs in clinical development," said Dr. Shrotriya. "Mr. Turgeon, working closely with Ken Keller, Executive Vice President, Chief Operating Officer, already has contributed greatly to executing our planned strategy for expedited growth of the Company under our recent commercial reorganization, and we are pleased to announce his promotion to CCO and responsibilities for our global commercial presence."

"Every day at Spectrum, we see new opportunities and new ways to apply our knowledge to further accelerate our momentum and increase our footprint in the market. Each of our current products on the market has a unique set of benefits for patients and unique abilities to address current needs, as is true of our late-stage development product candidates. With our commercial reorganization and drive to succeed, Spectrum is in a stronger position than ever to communicate these advantages to physicians and patients," stated Mr. Turgeon.

1 2 3 4 5 6 Next › Last »